BRCA2 Mutation as a Possible Cause of Poor Response to 177Lu-PSMA Therapy

Clinical Nuclear Medicine
Hojjat AhmadzadehfarMarkus Essler

Abstract

We present the case of a 66-year-old man with castration-resistant prostate cancer, with an increasing prostate-specific antigen level, and a progressive disease during Lu-PSMA radionuclide therapy. Because the patient had a BRCA2 mutation, poly-ADP ribose polymerase inhibitor therapy was started. The patient showed a dramatic subjective and biological response to this therapy with a progression-free survival of 5 months.

References

Oct 29, 2015·The New England Journal of Medicine·Joaquin MateoJohann S de Bono
Sep 3, 2016·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Justin FerdinandusHojjat Ahmadzadehfar
Oct 22, 2016·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Kambiz RahbarBernd Joachim Krause
Mar 25, 2017·European Journal of Nuclear Medicine and Molecular Imaging·Anna YordanovaHojjat Ahmadzadehfar
May 11, 2017·European Journal of Nuclear Medicine and Molecular Imaging·Hojjat AhmadzadehfarMarkus Essler
Feb 8, 2018·The New England Journal of Medicine·Oliver Sartor, Johann S de Bono

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Cancer: BRCA1 & BRCA2

Mutations involving BRCA1, found on chromosome 17, and BRCA2, found on chromosome 13, increase the risk for specific cancers, such as breast cancer. Discover the last research on breast cancer BRCA1 and BRCA2 here.